An effective malaria vaccine remains an important priority for the millions of people living in malaria endemic regions. Subambitious goals for the development of a vaccine have been set, which aim to achieve a licensed first-generation P. falciparum malaria vaccine with more than 50% protective efficacy against severe disease and death, lasting for at least 1 year by 2015. These goals were set in the context of a subunit vaccine. However, a whole-parasite vaccine might be expected to induce substantially superior protection. Our group has been focusing on low dose blood-stage parasites as a valid vaccine approach, and we present here the relevant methodology for this.
CITATION STYLE
Stanisic, D. I., & Good, M. F. (2012). Induction of Anti-Plasmodium Immunity Following Subpatent Infection with Live Erythrocytic Stages and Drug Cure (pp. 535–547). https://doi.org/10.1007/978-1-62703-026-7_37
Mendeley helps you to discover research relevant for your work.